MYCOPHENILIC ACID vs TACROLIMUS

Compare MYCOPHENILIC ACID (Mycophenolic Acid) and TACROLIMUS (Tacrolimus) — clinical data, side effects, and patient experiences.

MYCOPHENILIC ACID

Mycophenolic Acid · Immunosuppressant

How it works

12.1 Mechanism of Action Mycophenolic acid (MPA), an immunosuppressant, is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore i...

Approved for

See full prescribing information

OralTablet

TACROLIMUS

Tacrolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intrac...

Approved for

1 INDICATIONS AND USAGE Tacrolimus capsules are calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver

kidney or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney

Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection

in adult patients receiving allogeneic kidney transplant [ see Clinical Studies (14.1) ]

OralTablet

Quick Comparison

MYCOPHENILIC ACIDTACROLIMUS

Drug Class

Immunosuppressant

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MYCOPHENILIC ACID

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

Nausea

1-10%

Fatigue

0.1-1%

Headache

0.1-1%

Shortness of Breath

0.1-1%

TACROLIMUS

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

MYCOPHENILIC ACID

5 WARNINGS AND PRECAUTIONS New or Reactivated Viral Infections: Consider reducing immunosuppression
6 ) Serious GI Tract Complications (gastrointestinal bleeding, perforations and ulcers): Administer with caution to patients with active digestive system disease
1 Embryo-Fetal Toxicity Use of mycophenolic acid delayed-release tablets during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities, including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system
Females of reproductive potential must be aware of these risks and must be counseled regarding pregnancy prevention and planning

TACROLIMUS

5 WARNINGS AND PRECAUTIONS Not Interchangeable with Extended Release Tacrolimus Products-Medication Errors : Instruct patients or caregivers to recognize the appearance of tacrolimus capsules
5 ) Neurotoxicity: Including risk of Posterior Reversible Encephalopathy Syndrome (PRES), monitor for neurologic abnormalities; reduce or discontinue tacrolimus
9 ) Not recommended for use with sirolimus: Not recommended in liver and heart transplant due to increased risk of serious adverse reactions
1 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin

Clinical Trial Data

No head-to-head clinical studies found for MYCOPHENILIC ACID vs TACROLIMUS.

MYCOPHENILIC ACID vs TACROLIMUS: What You Should Know

Key Differences

Both MYCOPHENILIC ACID and TACROLIMUS belong to the Immunosuppressant class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients.

Safety Considerations

MYCOPHENILIC ACID carries 4 FDA warnings. TACROLIMUS carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

EVEROLIMUS vs MYCOPHENILIC ACID→MYCOPHENILIC ACID vs SIROLIMUS→CYCLOSPORINE OPHTHALMIC SOLUTION vs MYCOPHENILIC ACID→CYCLOSPORINE vs MYCOPHENILIC ACID→EVEROLIMUS vs TACROLIMUS→SIROLIMUS vs TACROLIMUS→

Loading comparison data...

MYCOPHENILIC ACID vs TACROLIMUS

Compare MYCOPHENILIC ACID (Mycophenolic Acid) and TACROLIMUS (Tacrolimus) — clinical data, side effects, and patient experiences.

MYCOPHENILIC ACID

Mycophenolic Acid · Immunosuppressant

How it works

12.1 Mechanism of Action Mycophenolic acid (MPA), an immunosuppressant, is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore i...

Approved for

See full prescribing information

OralTablet

TACROLIMUS

Tacrolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intrac...

Approved for

1 INDICATIONS AND USAGE Tacrolimus capsules are calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver

kidney or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney

Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection

in adult patients receiving allogeneic kidney transplant [ see Clinical Studies (14.1) ]

OralTablet

Quick Comparison

MYCOPHENILIC ACIDTACROLIMUS

Drug Class

Immunosuppressant

Route

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

MYCOPHENILIC ACID

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

Nausea

1-10%

Fatigue

0.1-1%

Headache

0.1-1%

Shortness of Breath

0.1-1%

TACROLIMUS

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

MYCOPHENILIC ACID

5 WARNINGS AND PRECAUTIONS New or Reactivated Viral Infections: Consider reducing immunosuppression
6 ) Serious GI Tract Complications (gastrointestinal bleeding, perforations and ulcers): Administer with caution to patients with active digestive system disease
1 Embryo-Fetal Toxicity Use of mycophenolic acid delayed-release tablets during pregnancy is associated with an increased risk of first trimester pregnancy loss and an increased risk of congenital malformations, especially external ear and other facial abnormalities, including cleft lip and palate, and anomalies of the distal limbs, heart, esophagus, kidney, and nervous system
Females of reproductive potential must be aware of these risks and must be counseled regarding pregnancy prevention and planning

TACROLIMUS

5 WARNINGS AND PRECAUTIONS Not Interchangeable with Extended Release Tacrolimus Products-Medication Errors : Instruct patients or caregivers to recognize the appearance of tacrolimus capsules
5 ) Neurotoxicity: Including risk of Posterior Reversible Encephalopathy Syndrome (PRES), monitor for neurologic abnormalities; reduce or discontinue tacrolimus
9 ) Not recommended for use with sirolimus: Not recommended in liver and heart transplant due to increased risk of serious adverse reactions
1 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin

Clinical Trial Data

No head-to-head clinical studies found for MYCOPHENILIC ACID vs TACROLIMUS.

MYCOPHENILIC ACID vs TACROLIMUS: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.